Video wird geladen...

Video konnte nicht geladen werden

Zur Startseite

‘Specialty drugs’ might be unique, but access should not be special - why? Because needing a specialty medication shouldn’t mean jumping through hoops or facing unpredictable pricing. We believe access to life-changing medications should be simple, direct, and free from hidden fees. That’s why we carry specialty drugs like:...

107,814 Aufrufe • vor 1 Jahr •via X (Twitter)

3 Kommentare

Profilbild von subhojit chakraborty
subhojit chakrabortyvor 1 Jahr

to be great !

Profilbild von STAT
STATvor 1 Jahr

When patents for name brand medicines expire, the price of that medicine drops significantly as generic versions enter the market, but that process can take a while. Watch a new video in STAT's 'Behind the Counter' series:

Profilbild von The Banana Rat
The Banana Ratvor 1 Jahr

i am doing some formulary research in Canada and ask if you know of or have found any new studies or papers speaking to the long-term impact of GLP-1 use on improving health outcomes and reducing overall healthcare costs, particularly related to CPAP, diabetes, and cardiovascular disease? The broader system-wide ROI may be more significant than the upfront price suggests. Cheers, 🍌🐀

Ähnliche Videos

Here are my solutions for the border. Keep in mind that I realize there is no exact science here and no fool-proof solution. - Immigration must be opened up. More people should be able to come here legally, seek work here, and raise children here. - No we don’t need a wall from sea to shining sea. We do need more fencing/wall built though in areas where it makes sense. - The walls need to be much more difficult to climb over and tunnel under, and they must be equipped with modern technology and reinforced with border agents every 1/2 mile or so where feasible. - Fencing should extend deep into the ground where possible. Every inch of wall should be monitored with cameras mounted in a way that makes them impossible to be damaged. No fence is fool-proof but they can definitely be better than what Trump built and what we’ve been building for years. - In areas where there is no fencing — most notably in areas where the land is owned by Americans and around obstacles like the Rio Grande, we should exponentially hire additional border agents and utilize more cameras and more video. We should work with Mexico to to create a neutral zone currently in Mexico to allow US agents to patrol as well, or make sure that Mexico is patrolling those areas up to our standards. - Every single person looking to come into America should be required to show some sort of legitimate reason to seek asylum before even being granted access. If they don’t have one that can be shown or proven immediately, there needs to be a process for them to do so within their own country and within Mexico, but with a caveat: The US should man special safe asylum centers in various Central and South American countries, as well as in Mexico. American citizens should run these centers, and asylum judges should be stationed there to expedite the process. The asylum seekers should be fed and cared for during the time they are there. Massive amounts of asylum judges and border agents need to be hired. I can’t reiterate this enough. We need a lot of funding and training for this. - Every person seeking asylum should be recorded through a biometric system so that repeated attempts can quickly and easily be identified. Thoughts?

Ed Krassenstein

1,099,788 Aufrufe • vor 2 Jahren

My wife and I own a pharmacy. Last month we spent days trying to pry one prescription loose from a company that did everything it could to hold onto it. The drug was everolimus. A generic. It treats cancer and protects transplant patients from rejecting their new organ. Not exotic. Not rare. A pill. The patient wanted it filled with us because we're cash-pay and cost-plus. No insurance. No PBM. No secret markups, no games. Our price was $318. That's not cheap by our standards — most of what we fill runs under $20 — but it was honest. Here's what that same prescription looked like on the other side of the counter. In 2023, Medicare was paying about $6,645 for it. That's roughly 21 times our price for the identical medication. Medicare spent around $240 million on everolimus alone that year. If they'd paid our price, they'd have saved roughly $230 million. On one generic drug. So how does an insurance company profit off a drug that expensive? Don't they pay for it? No. You pay for it. In your premiums. Their job isn't to spend less — it's to keep your healthcare dollars circulating inside their own companies. And the tool they use is called spread pricing. Spread pricing works like this: the middleman bills the health plan one price, pays the pharmacy a lower one, and keeps the difference. You never see it. On TRICARE, they pay an independent pharmacy like mine about $311 to fill everolimus. That barely covers our cost of the drug. Meanwhile the plan gets billed thousands. That gap — north of $6,000 on a single fill — is pure margin the middleman pockets. Now here's the part they'd rather you not think about. The pharmacy we were fighting was Accredo. Accredo is owned by Express Scripts. Express Scripts is the pharmacy benefit manager owned by Cigna. Same company, three masks. That nesting-doll structure isn't an accident — it's the whole design. When the pharmacy, the PBM, and the insurer are all one entity, they can shuffle money between their own pockets and call it whatever they want. The confusion is the product. And this isn't a story about one weird drug. It's the business model. The FTC has been digging into exactly this. In its January 2025 report on the three biggest PBMs — CVS Caremark, Express Scripts, and OptumRx — staff found those companies marked up specialty generic drugs by hundreds and thousands of percent when dispensing through their own affiliated pharmacies. Just those markups generated more than $7.3 billion above what the drugs actually cost to acquire, from 2017 to 2022. One in five of the specialty generics they studied was marked up over 1,000%. Some cancer generics: over 3,000%. On top of that, the FTC pegged spread pricing on those same drugs at another $1.4 billion. One example straight from the FTC's files: dimethyl fumarate, a multiple sclerosis drug. Costs about $177 to acquire. The PBMs paid their own pharmacies close to $4,000 for a 30-day supply. Same trick. Different drug. And they steer the profitable ones to themselves on purpose. Pharmacies affiliated with the big three took in 68% of specialty dispensing revenue in 2023 — up from 54% in 2016. The prescriptions marked up more than $1,000 disproportionately end up at their own pharmacies, not independents like mine. So when we called to transfer this patient's everolimus to be filled without insurance, it landed like we were asking them to set $6,000 on fire. Of course they stonewalled us. That's why we fired them. No insurance means no invisible $6,000 charge buried in a premium you can't itemize. It means the price you see is the price. Ours was $318. Theirs was thousands. Same pill.

Forest Park Pharmacy

58,395 Aufrufe • vor 26 Tagen